{
  "paper_metadata": {
    "pmid": "29262651",
    "title": "MAIN TEXT",
    "extraction_summary": "The paper discusses the clinical implications of germline BRCA1/2 mutations in patients treated with PARP inhibitors, specifically focusing on the BRCA2 gene. It provides insights into the penetrance of BRCA2 mutations and their association with radiological differential responses (RDR) during treatment."
  },
  "variants": [
    {
      "gene_symbol": "BRCA2",
      "cdna_notation": "c.W563*",
      "protein_notation": "p.W563*",
      "genomic_position": null,
      "clinical_significance": "pathogenic",
      "patients": {
        "count": 1,
        "demographics": "52-year-old female",
        "phenotype": "metastatic papillary serous ovarian cancer"
      },
      "penetrance_data": {
        "total_carriers_observed": 79,
        "affected_count": 39,
        "unaffected_count": 40,
        "uncertain_count": null,
        "penetrance_percentage": 49.4,
        "age_dependent_penetrance": []
      },
      "individual_records": [
        {
          "individual_id": "Case_1",
          "age_at_evaluation": 52,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "female",
          "affected_status": "affected",
          "phenotype_details": "metastatic papillary serous ovarian cancer",
          "evidence_sentence": "She was a 52-year-old female with metastatic papillary serous ovarian cancer, who was known to harbor a deleterious germline BRCA2 mutation (p.W563*)."
        }
      ],
      "functional_data": {
        "summary": "The patient demonstrated a complete response to PARP inhibitor therapy initially, but developed a new solitary liver metastasis after 81 months.",
        "assays": [
          "targeted NGS"
        ]
      },
      "segregation_data": "The variant is associated with disease in the individual case presented.",
      "population_frequency": null,
      "evidence_level": "strong",
      "source_location": "Results, paragraph 4",
      "additional_notes": "The patient had a sustained complete response to PARP inhibitor therapy for 81 months before developing a new metastasis.",
      "key_quotes": [
        "She was a 52-year-old female with metastatic papillary serous ovarian cancer, who was known to harbor a deleterious germline BRCA2 mutation (p.W563*).",
        "After 81 months of a sustained CR to PARP inhibitor monotherapy, CT imaging revealed a new solitary liver metastasis."
      ]
    }
  ],
  "tables_processed": [],
  "extraction_metadata": {
    "total_variants_found": 1,
    "extraction_confidence": "high",
    "challenges": [],
    "notes": "The extraction focused solely on the BRCA2 gene as per the instructions."
  }
}